LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

Kodu・Aktsiate loetelu・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Suletud

10.44 4.61

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

9.68

Max

10.46

Põhinäitajad
By Trading Economics
Sissetulek	4.2M -23M
Kasumimarginaal	-2,027.003
Töötajad	83
EBITDA	6.6M -23M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+37.39% upside

Turustatistika
By TradingEconomics
Turukapital	123M 710M
Eelmine avamishind	5.83
Eelmine sulgemishind	10.44

Ventyx Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. nov 2025, 16:56 UTC

Tulu

Suurimad hinnamuutused turgudel

Alimentation Couche-Tard Shares Rise as 2Q Same-Store Sales Support Profit Growth

25. nov 2025, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25. nov 2025, 23:47 UTC

Market Talk

Nikkei May Rise After Stock Gains on Wall Street -- Market Talk

25. nov 2025, 22:39 UTC

Market Talk

Global Equities Roundup: Market Talk

25. nov 2025, 22:39 UTC

Market Talk

Vault Accelerates Exposure to Spot Gold Prices by Six Months -- Market Talk

25. nov 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

25. nov 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

25. nov 2025, 21:38 UTC

Tulu

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25. nov 2025, 21:31 UTC

Market Talk

F&P Healthcare's Share Price Jumps on Profit Guidance Upgrade -- Market Talk

25. nov 2025, 21:27 UTC

Tulu

These Stocks Moved the Most Today: Nvidia, AMD, Alphabet, Abercrombie, Kohl's, Novo Nordisk, Symbotic, and More -- Barrons.com

25. nov 2025, 21:20 UTC

Tulu

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25. nov 2025, 21:18 UTC

Tulu

NIO Stock Drops as EV Maker Posts Narrower Loss -- Barrons.com

25. nov 2025, 21:15 UTC

Tulu

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25. nov 2025, 20:16 UTC

Market Talk

U.S. Natural Gas Falls as December Contract Expires -- Market Talk

25. nov 2025, 18:42 UTC

Market Talk

USDA Backs Mexican Retail Expo to Raise Agricultural Exports -- Market Talk

25. nov 2025, 18:25 UTC

Omandamised, ülevõtmised, äriostud

S&P Global Completes $1.8 Billion Acquisition Of With Intelligence, Strengthening Its Position As A Leader In Private Markets Data & Analytics >SPGI

25. nov 2025, 17:30 UTC

Market Talk

Mexico Posts Record Foreign Direct Investment for Jan-Sep -- Market Talk

25. nov 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

25. nov 2025, 17:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

25. nov 2025, 16:33 UTC

Omandamised, ülevõtmised, äriostud

Eni: Financial Details Weren't Disclosed

25. nov 2025, 16:33 UTC

Omandamised, ülevõtmised, äriostud

Eni: Block OFF-5 Covers an Area of About 17,000 Km Sq. in Water Depths

25. nov 2025, 16:32 UTC

Omandamised, ülevõtmised, äriostud

Eni: Agreement to Become Effective After Approval of Uruguayan Authorities

25. nov 2025, 16:31 UTC

Omandamised, ülevõtmised, äriostud

Eni: Acquisition Is for a 50% Share, Operatorship in Exploration Block OFF-5

25. nov 2025, 16:30 UTC

Omandamised, ülevõtmised, äriostud

Eni Acquires From YPF Shares in the Exploration Block OFF-5 Offshore Uruguay

25. nov 2025, 16:23 UTC

Tulu

This Robotics Stock Soars 40% on Earnings. Here's Why. -- Barrons.com

25. nov 2025, 16:12 UTC

Market Talk

Euro Expected to Rise to $1.25 in 2026: Deutsche Bank -- Market Talk

25. nov 2025, 16:11 UTC

Market Talk

Dollar Could Take One Final Leg Lower in Early 2026 -- Market Talk

25. nov 2025, 16:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25. nov 2025, 16:10 UTC

Market Talk

Sterling Could Briefly Rise After Budget -- Market Talk

25. nov 2025, 16:10 UTC

Market Talk

Oil Extends Losses on Ukraine-Russia Peace Deal Hopes -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Ventyx Biosciences Inc Prognoos

Hinnasiht

By TipRanks

37.39% tõus

12 kuu keskmine prognoos

Keskmine 13.67 USD 37.39%

Kõrge 21 USD

Madal 2 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Ventyx Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Ventyx Biosciences Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.